Medicare Enrolled

Dr. Alexander Gershman, MD

Optician · Los Angeles, CA
Practice pattern: Clinical Cardiology — Primarily office-based clinical cardiology
Low-engagement
6404 WILSHIRE BLVD STE 701, Los Angeles, CA 90048
3106231911
In practice since 2006 (19 years)
NPI: 1124058219 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Gershman from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Gershman? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Gershman

Dr. Alexander Gershman is an optician specialist in Los Angeles, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Gershman performed 14,079 Medicare services across 8,482 unique beneficiaries.

Between the years covered by Open Payments, Dr. Gershman received a total of $7,135 from 50 pharmaceutical and/or device companies across 296 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in optician. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Gershman is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice ▲ Top 6% volume in CA $7,135 industry payments

Medicare Practice Summary

Medicare Utilization ↗
14,079
Medicare services
Top 6% in CA for optician
8,482
Unique beneficiaries
$88
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~741 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Urinalysis, manual
A manual laboratory examination of a urine sample to check for various substances and cells.
1,908 $3 $15
Complete pelvic ultrasound
An imaging test using sound waves to create pictures of the organs and structures within the pelvis.
1,665 $63 $400
Complete ultrasound of retroperitoneum
An ultrasound examination of the structures located behind the abdominal cavity.
1,664 $94 $400
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
1,341 $107 $350
Electronic assessment of bladder emptying
A test that uses electronic monitoring to evaluate how well the bladder empties urine.
1,241 $11 $100
Office visit, established patient, complex (40-54 min)
An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter.
948 $145 $400
Injection, garamycin, gentamicin, up to 80 mg 941 $2 $5
On-body injector for subcutaneous injection
A device is applied to the skin to automatically deliver a medication injection under the skin.
564 $16 $60
Lower leg neurostimulator electrode insertion
A procedure to place an electrode in the lower leg for neurostimulation therapy.
493 $106 $450
Limited ultrasound of pelvis
A focused ultrasound exam of the pelvic area to evaluate specific structures. This procedure provides images of the pelvis to assist in medical assessment.
334 $35 $150
Leuprolide acetate (for depot suspension), 7.5 mg 324 $136 $600
New patient office visit (45-59 min)
An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter.
260 $127 $350
Endoscopic destruction of bladder/urethra growth, less than 0.5 cm
A procedure to remove abnormal tissue growths from the bladder or urethra using an endoscope. This specific code applies when the growths are smaller than 0.5 centimeters.
241 $716 $2,700
Urethral dilation using endoscope
A procedure to widen the urethra using a thin, lighted tube called an endoscope. This helps to open a narrowed urethral passage.
188 $293 $1,050
Home health plan of care certification
Certification by a physician or allowed practitioner for Medicare-covered home health services under a home health plan of care. This includes contacting the home health agency and reviewing reports of patient status required by physicians.
174 $46 $200
Home visit, established patient, moderate complexity
A home visit for an established patient involving moderate medical decision making. The visit requires at least 40 minutes of time if time is used to determine the level of service.
163 $105 $453
Electrical stimulation therapy
Application of electrical stimulation to one or more body areas as part of a therapy plan. This procedure is used for indications other than wound care.
163 $11 $60
Endoscopic destruction of bladder, urethra, or gland tissue
A procedure that uses an endoscope to destroy tissue in the bladder, urethra, or surrounding glands.
144 $688 $2,500
Telephone medical discussion, 21-30 minutes
A telephone conversation with a physician lasting between 21 and 30 minutes. This code covers the time spent discussing medical matters over the phone.
143 $89 $430
Home health plan of care re-certification
A physician reviews the patient's status and contacts the home health agency to re-certify the plan of care without the patient being present.
134 $37 $150
Biofeedback training for bowel or bladder control, initial 15 minutes
A 15-minute session using biofeedback techniques to help patients gain control over bowel or bladder functions. The training involves monitoring physiological processes to learn how to manage muscle activity.
129 $72 $300
Ultrasound of scrotum
An imaging test that uses sound waves to create pictures of the scrotum and its contents. It helps evaluate the testicles and surrounding structures.
113 $63 $350
Subcutaneous or intramuscular chemotherapy injection
This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle.
108 $31 $120
Non-needle muscle activity measurement of bladder and bowel openings
This procedure measures and records the electrical activity of muscles at the bladder and bowel openings without using needles.
94 $41 $250
Office visit for established patient
An office visit for an existing patient that may not require the healthcare professional to be present.
57 $21 $87
Cystourethroscopy
A diagnostic exam of the bladder and urethra using an endoscope to visually inspect the urinary tract.
56 $123 $700
Transrectal ultrasound of the pelvis
An ultrasound imaging procedure where a probe is inserted into the rectum to visualize pelvic structures.
54 $123 $500
Simple change of bladder tube 52 $87 $300
Ultrasound guidance for needle placement
Use of ultrasound imaging to guide the precise placement of a needle during a medical procedure.
50 $51 $200
Complex urodynamic pressure flow study
A test that measures the pressure of urine flow in the bladder during voiding to evaluate how well the bladder and urethra are functioning.
49 $333 $1,200
Abdominal device insertion with pressure and urine flow study
A procedure involving the placement of a device into the abdomen, accompanied by a study to measure pressure and urine flow rate.
49 $178 $500
Complicated insertion of bladder tube 46 $130 $450
Rectal sensitivity and function study
A test to evaluate the sensitivity and functional performance of the rectum.
45 $249 $900
Assessment of and care planning for patient with impaired thought processing, typically 60 minutes 35 $236 $900
Prostate gland biopsy
A procedure to remove small samples of tissue from the prostate gland for laboratory examination.
26 $213 $900
Prostate tissue destruction using radiofrequency heated water vapor
A procedure that destroys prostate tissue by using radiofrequency energy to heat water vapor. This method is applied to treat the prostate gland.
24 $1,552 $6,600
Home visit, established patient, high complexity
A home visit for an established patient involving high-level medical decision making, lasting at least 60 minutes.
22 $151 $434
New patient office visit, complex (60-74 min) 13 $188 $450
Home visit, new patient, moderate complexity
A home visit for a new patient involving moderate medical decision making, lasting at least 60 minutes.
13 $120 $600
Transurethral prostate removal with electrocautery
This procedure involves removing the prostate gland through the urethra using an endoscope and an electrocautery knife to control bleeding.
11 $570 $3,000
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$7,135
Total received (2018-2024)
Avg $1,019/year across 7 years
Top 18% in CA for optician
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
50
Companies
296
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$7,002 (98.1%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$134 (1.9%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$1,123
2023
$746
2022
$1,199
2021
$895
2020
$746
2019
$1,182
2018
$1,245

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Sumitomo Pharma America, Inc.
$251
Dendreon Pharmaceuticals LLC
$235
Boston Scientific Corporation
$152
PFIZER INC.
$139
COLOPLAST CORP
$88
Teleflex LLC
$80
UROGEN PHARMA, INC.
$58
Astellas Pharma US Inc
$24
Novo Nordisk Inc
$23
Endo Pharmaceuticals Inc.
$22
Calyxo, Inc.
$18
PROGENICS PHARMACEUTICALS, INC.
$18
ACCORD HEALTHCARE, INC.
$15
Top 3 companies account for 56.8% of 2024 payments
All-time payments by company (2018-2024) ›
Astellas Pharma US Inc
$1,251
PFIZER INC.
$756
Boston Scientific Corporation
$734
Amgen Inc.
$551
Sumitomo Pharma America, Inc.
$515
Dendreon Pharmaceuticals LLC
$481
Allergan Inc.
$238
Teleflex LLC
$237
Endo Pharmaceuticals Inc.
$223
BOSTON SCIENTIFIC CORPORATION
$219
UROVANT SCIENCES INC
$210
Acerus Pharmaceuticals Corporation
$134
Myriad Genetic Laboratories, Inc.
$122
COLOPLAST CORP
$120
Coloplast Corp
$100
AMAG Pharmaceuticals, Inc.
$94
Profound Medical Corp.
$90
Myovant Sciences Inc.
$84
Takeda Pharmaceuticals U.S.A., Inc.
$66
UroGen Pharma, Inc.
$60
Progenics Pharmaceuticals, Inc.
$59
UROGEN PHARMA, INC.
$58
Ethicon US, LLC
$46
MEDIVATION FIELD SOLUTIONS LLC
$41
Novo Nordisk Inc
$41
Mission Pharmacal Company
$40
BAXTER HEALTHCARE
$34
Metuchen Pharmaceuticals
$33
Ferring Pharmaceuticals Inc.
$33
Intuitive Surgical, Inc.
$32
ABBVIE INC.
$31
Janssen Biotech, Inc.
$28
Horizon Therapeutics plc
$27
Axonics, Inc.
$26
180 Medical, Inc.
$25
Hikma Pharmaceuticals USA
$24
C. R. Bard, Inc. & Subsidiaries
$24
GlaxoSmithKline, LLC.
$22
Avadel Specialty Pharmaceuticals, LLC
$22
Augmenix, Inc.
$22
Duchesnay USA Incorporated
$21
AKRIMAX PHARMACEUTICALS, LLC
$20
Merck Sharp & Dohme LLC
$19
Laborie Medical Technologies Corp.
$19
UroViu Corporation
$19
Calyxo, Inc.
$18
PROGENICS PHARMACEUTICALS, INC.
$18
COVIDIEN LP
$18
ACCORD HEALTHCARE, INC.
$15
Hollister Incorporated
$14
Top 3 companies account for 38.4% of all-time payments
Associated products mentioned in payments ›
AMS · AMS 700 · AMS 700 CXR RTE Kit · AMS Ambicor · AVYCAZ · AdVance XP · Altis · Amitiza · BOTOX · BOTOX THERAPEUTIC · Bard Urinary Drainage Bag · Bulkamid · CAMCEVI · CVAC ASPIRATION SYSTEM · Da Vinci Surgical System · Dexilant · EVENITY · Erleada · FLOSEAL · GEMTESA · GENERAL ERECTILE DYSFUNCTION · GENERAL BPH · INTRAROSA · JELMYTO · KEYTRUDA · KRYSTEXXA · LIGASURE · MYRBETRIQ · Mitigare · Motegrity · Myrbetriq · NOCDURNA · NUCALA · Natesto · Noctiva · ONLI · ORGOVYX · Osphena · PREMARIN · PROVENGE · PVC · PYLARIFY · Prolaris · Prolia · Rezum Generator · SOLESTA · STRATAFIX · SURGIFLO Hemostatic Matrix Family of Products · Solyx SIS System · SpaceOAR · SpeediCath · Stendra · TITAN · TOVIAZ · Titan · Tulsa-Pro · Uribel · Uro-G Flexible Cystoscope · UroLift System · Urocit-K · VESICARE · Veozah · Wegovy · XIAFLEX · XTANDI · ZYTIGA · rezum Generator
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (98%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Looking for an optician specialist in Los Angeles?
Compare opticians in the Los Angeles area by procedure volume, costs, and industry payment transparency.
Browse opticians nearby

Geographic Context

Opticians within 10 mi
1,540
Per 100K population
15.6
County median income
$87,760
Nearest hospital
CEDARS-SINAI MEDICAL CENTER
0.0 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Gershman is a clinical cardiology specialist, with above-average Medicare volume (top 6% in CA), with low-engagement industry engagement in the top 18% of CA peers, with 19 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Gershman experienced with urinalysis, manual?
Based on Medicare claims data, Dr. Gershman performed 1,908 urinalysis, manual services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Gershman receive payments from pharmaceutical companies?
Yes. Dr. Gershman received a total of $7,135 from 50 companies across 296 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Gershman's costs compare to other opticians in Los Angeles?
Dr. Gershman's average Medicare payment per service is $88. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Gershman) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →